硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响

Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I

    摘要
  • 摘要:
    目的 探讨Graves病患者经131I治疗后，补硒对患者血清甲状腺过氧化物酶抗体（TPOAb）水平的影响。
    方法 选取TPOAb水平为10~1300 IU/ml的Graves病患者266例，其中，TPOAB范围在10~60 IU/ml为阴性，TPOAb > 60 IU/ml为阳性。将所有患者随机分成对照组（112例）和硒治疗组（154例），对照组经131I治疗后行常规治疗，硒治疗组经131I治疗后行常规治疗及服硒制剂（100 μg/次，2次/d），比较两组治疗后6、12个月TPOAb水平及TPOAb阳性率的变化。
    结果 治疗后6个月，两组TPOAb水平较治疗前均明显上升，且差异有统计学意义（对照组：Z=－2.084，P < 0.05；硒治疗组：Z=－2.112，P < 0.05），但两组之间的差异无统计学意义（Z=－0.764，P>0.05）；治疗后12个月，对照组TPOAb水平与治疗前相比差异无统计学意义（Z=-1.538，P>0.05），硒治疗组TPOAb水平与治疗前相比差异有统计学意义（Z=－5.465，P < 0.01），两组间比较差异有统计学意义（Z=-2.180，P < 0.05）；两组TPOAb水平阳性率在治疗后6、12个月与治疗前相比无明显变化（对照组：x12=0.720、x22=0.103，P均>0.05；硒治疗组：x12=0.023、x22=0.340，P均>0.05），两组间比较差异亦无统计学意义（x12=0.001、x22=0.366，P均>0.05）。
    结论 结论补硒能有效降低经131I治疗的Graves病患者的血清TPOAb水平，对血清高水平TPOAb的降低尤为明显。

     

    Abstract:
    Objective To explore the effect of additional selenium on the serum levels of thyroid peroxidase antibody(TPOAb) after treatment of Graves disease with 131I.
    Methods A total of 266 patients with TPOAb levels between 10 and 1300 IU/ml participated in this study. TPOAb levels within 10 IU/ml to 60 IU/ml were considered negative, and levels greater than 60 IU/ml were considered positive. All patients were randomly divided into control(n=112) and selenium treatment group(n=154). After treatment with 131I, the control group received conventional therapy, whereas the selenium treatment group received additional selenium(100 μg twice a day). The TPOAb levels and positive ratios of the two groups were compared with pre-therapy levels after treatment for 6 and 12 months.
    Results After 6 months, the TPOAb levels in both groups significantly increased compared with the pre-therapy levels(control group:Z=-2.084, P < 0.05; selenium treatment group:Z=-2.112, P < 0.05). However, no significant difference existed in the TPOAb levels between the two groups(Z=-0.764, P > 0.05). After 12 months, the TPOAb levels in the control group did not change significantly compared with the pre-therapy levels(Z=-1.538, P > 0.05), whereas the TPOAb levels in the selenium treatment group significantly decreased compared with the pre-therapy levels(Z=-5.465, P < 0.01). The difference between the two groups were statistically significant(Z=-2.180, P < 0.05). The positive ratios of TPOAb for both groups did not change significantly 6 or 12 months after 131I therapy(control group:x12= 0.720, x22=0.103, both P > 0.05; selenium treatment group:x12=0.023, x22=0.340, both P > 0.05). Overall, the positive ratios were not statistically significant between the two groups(x12=0.001, x22=0.366, both P > 0.05).
    Conclusion Additional treatment with selenium after 131I therapy for Graves disease can effectively decrease the TPOAb levels, especially for patients with high initial TPOAb levels.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回